About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
 
  About Us
  Research & Development
  Biopharmaceuticals
  Branded Formulations
  Financial Results
  - Investor Call Invite
  - Investor Presentation
  - Chairman's Speech 2017
  - Disclosure to Stock Exchange
  - Annual Reports

 Annual Report 2018

Annual Report 2018

  Downloads
  - Enduring Edge: Biocon's Journey of Endurance
  - Biocon Profile
  - CMD Profile
  - Video Gallery
 
 
 


 
 
 

Biocon Malaysia


 

  Biocon Academy

Email:
admissions@bioconacademy.com

  Facilities Virtual Tour
     
 

Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world.

We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.

Biocon is among the few companies globally to have received approvals for its biosimilars from developed countries like the U.S., EU, Australia and Japan. Our credibility as a serious player in the biosimilars sector was first established with the Japanese approval for Insulin Glargine. The credibility was enhanced when Biocon, along with partner Mylan, became the first globally to get biosimilar Trastuzumab and Pegfilgrastim approved in the U.S. in 2017 and 2018, respectively. We were also among the first few to receive Insulin Glargine approval in Europe and Australia for Insulin Glargine, both in partnership with Mylan. We have also established our presence in key emerging markets through safe, effective and high quality biosimilars including recombinant human insulin.

A combination of specialized talent, state-of-the-art research and manufacturing infrastructure and a culture of deep science and regulatory compliance have differentiated us in the marketplace and given us a distinct competitive edge. It has also led to Biocon being recognized as a credible global biopharmaceuticals player.

read more...

 
   

Biocon Q1FY19 Performance Highlights by Kiran Mazumdar-Shaw, CMD, Biocon





Keynote Address delivered by Kiran Mazumdar-Shaw, CMD, Biocon at the GAP Summit 2018




Biocon: Engaged in Affordable
Innovation for Global Impact
Stock Update
 

 

Company Announcements

 
 

September 22, 2018 
 Biocon’s Drug Substance Facility in Bangalore completes U.S. FDA Inspection with No observations

September 21, 2018 
 Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

July 26, 2018 
 Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr

July 04, 2018 
 Biocon's Sterile Drug Product facility receives EU GMP Certification

June 28, 2018 
 Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA

June 23, 2018 
 Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA

June 4–5, 2018 
 U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®

 
 
  Media Coverage  
 

  Apr 27, 2018:   Biocon Q4 profit rises 2% to Rs130 crore

 Mar 27, 2018:   Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for SemgleeTM, Biosimilar Insulin Glargine

 
 

Contact

Contact

Contact

Contact

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved